Dawson James analyst Jason Kolbert maintained a Buy rating on Cytosorbents (CTSO - Research Report) on August 3 and set a price target of $16.00. The company's shares closed last Friday at $2.10.Kolbert covers the Healthcare sector, focusing on stocks such as Sorrento Therapeutics, Can-Fite BioPharma, and Citius Pharmaceuticals. According to TipRanks, Kolbert has an average return of -0.9% and a 36.50% success rate on recommended stocks. Currently, the analyst consensus on Cytosorbents is a Moderate Buy with an average price target of $12.50, representing a 495.24% upside. In a report released on August 3, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.
https://www.tipranks.com/news/blurbs/dawson-james-sticks-to-its-buy-rating-for-cytosorbents-ctso?utm_source=advfn.com&utm_medium=referral
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more CytoSorbents Charts.
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more CytoSorbents Charts.